NCT01738698终止3 期
A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, 12-week, Forced-dose Titration Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 40mg, 100mg, or 160mg as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- Shire
- 入组人数
- 4
- 试验地点
- 1
- 主要终点
- Change From Baseline in Negative Symptom Assessment - 16-item (NSA-16) Total Score at 12 Weeks
研究概览
简要总结
The primary purpose of this study is to determine whether SPD489 40 mg, 100 mg, and 160 mg are effective and safe in the treatment of Negative Symptoms of Schizophrenia (NSS).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 to 65 years of age
- •Has a reliable informant (eg, family member, social worker, caseworker, or nurse that spends >4 hours/week with the subject)
- •Fixed home/place of residence and can be reached by telephone
- •On a stable dose of antipsychotic medications
- •Able to swallow capsules
排除标准
- •Taking lithium, carbamazepine, lamotrigine, gabapentin, cholinesterase inhibitors, modafinil, or other stimulants such as methylphenidate and other amphetamine products
- •Treated with clozapine in past 30 days
- •Lifetime history of stimulant, cocaine, or amphetamine abuse or dependence
- •History of seizures (other than infantile febrile seizures), any tic disorder, or current diagnosis and/or a known family history of Tourette's Disorder, serious neurological disease, history of significant head trauma, dementia, cerebrovascular disease, Parkinson's disease, or intracranial lesions
- •Uncontrolled hypertension
- •History of thyroid disorder that has not been stabilized on thyroid medication
- •Pregnant or nursing
- •Subject has received an investigational product or participated in a clinical study within 30 day
研究组 & 干预措施
SPD489 40mg
Experimental
干预措施: SPD489 40mg (Drug)
SPD489 100mg
Experimental
干预措施: SPD489 100mg (Drug)
SPD489 160mg
Experimental
干预措施: SPD489 160mg (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Baseline in Negative Symptom Assessment - 16-item (NSA-16) Total Score at 12 Weeks
时间窗: Baseline and 12 weeks
次要结局
- Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at 12 Weeks(Baseline and 12 weeks)
- Change From Baseline in Social Functioning Scale (SFS) at 12 Weeks(Baseline and 12 weeks)
- Change From Baseline in the Personal and Social Performance Scale (PSP) Score at 12 Weeks(Baseline and 12 weeks)
- Change From Baseline in Cognitive Test Battery (CogState Battery) Score at 12 Weeks(Baseline and 12 weeks)
- Ambulatory Blood Pressure Monitoring (ABPM)(Baseline and Weeks 4 and 10)
- Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at 12 Weeks(Baseline and 12 weeks)
- Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) at 12 Weeks(Baseline and 12 weeks)
- Change From Baseline in Clinical Evaluation of Harmful Behavior (CEHB) Scale at 12 Weeks(Baseline and 12 weeks)
- Clinical Global Impression-Schizophrenia Severity of Illness (CGI-SCH-S) Scale(Baseline and week 12)
- Columbia-Suicide Severity Rating Scale (C-SSRS)(Up to 12 weeks)
- Change From Baseline in Simpson Angus Scale (SAS) Total Score at 12 Weeks(Baseline and 12 weeks)
- Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at 12 Weeks(Baseline and 12 weeks)
- Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at 12 Weeks(Baseline and 12 weeks)
- Clinical Global Impression-Schizophrenia Degree of Change (CGI-SCH-C) Scale(Up to 12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
终止
3 期
SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of SchizophreniaSchizophreniaNCT01760889Shire1
已完成
3 期
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating DisorderBinge Eating DisorderNCT01718483Shire383
已完成
3 期
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating DisorderBinge Eating DisorderNCT01718509Shire390
撤回
3 期
Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)ADHDNCT01274221Shire
撤回
3 期
SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of SchizophreniaNegative Symptoms of SchizophreniaNCT01234298Shire